Insight

Andrea Necchi: Results from the ECHO-307/KEYNOTE-672 study

Andrea Necchi/youtube.com

Jul 26, 2024, 19:39

Andrea Necchi: Results from the ECHO-307/KEYNOTE-672 study

Andrea Necchi, Associate Professor at Vita-Salute San Raffaele University, shared on X:

“IDO1 inhibition was ineffective in urothelial carcinoma.

Pembrolizumab and epacadostat/placebo for cis-ineligible urothelial carcinoma:

ECHO-307/KEYNOTE-672 study, BMC Cancer, also negatively tested in neoadjuvant setting.”

Source: Andrea Necchi/X

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study.

Authors: Andrea Necchi, Michiel S. Van der Heijden, Dmytro Trukhin, Avivit Peer, Howard Gurney, Boris Y. Alekseev, Francis X. Parnis, Raya Leibowitz, Maria De Santis, Petros Grivas, Jason Clark, Mihaela Munteanu, Ritesh Kataria, Calvin Jia, Arjun V. Balar and Ronald de Wit.

Andrea Necchi

Andrea Necchi Arjun V. Balar Avivit Peer BMC Cancer Boris Y. Alekseev Calvin Jia cancer Dmytro Trukhin ECHO-307/KEYNOTE-672 study epacadostat Francis X. Parnis Howard Gurney Jason Clark Maria De Santis Michiel S. Van der Heijden Mihaela Munteanu OncoDaily Oncology pembrolizumab Petros Grivas Raya Leibowitz Ritesh Kataria Ronald de Wit urothelial carcinoma Vita-Salute San Raffaele University

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer